Equities

ELEVAI Labs Inc

ELAB:NAQ

ELEVAI Labs Inc

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (USD)0.6503
  • Today's Change0.000 / 0.05%
  • Shares traded73.91k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 13 2024 20:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elevai Labs, Inc. is a physician-dispensed skincare company. The Company conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. It produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare product lines. It has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.

  • Revenue in USD (TTM)1.71m
  • Net income in USD-4.30m
  • Incorporated2020
  • Employees18.00
  • Location
    ELEVAI Labs Inc120 Newport Center Drive, Ste 250NEWPORT BEACH 92660United StatesUSA
  • Fax+1 (302) 636-5454
  • Websitehttps://elevaiskincare.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Guardion Health Sciences Inc12.25m158.03k10.56m9.0066.191.2959.520.86230.12430.12439.666.390.7292.365.831,360,951.000.9405-77.901.12-86.5544.0442.451.29-176.936.98--0.00--10.8567.03101.00---58.56--
Moleculin Biotech Inc0.00-29.77m10.60m18.00--0.4067-----15.06-15.060.0011.700.00----0.00-62.25-46.84-70.87-51.49------------0.00-------2.56---21.54--
BioCardia Inc477.00k-11.57m10.64m16.00------22.30-0.5525-0.55250.0225-0.06770.0747--3.6129,812.50-181.08-107.34-414.21-154.17-----2,425.79-1,779.24---------64.72-5.262.82---28.89--
Mira Pharmaceuticals Inc0.00-11.98m10.64m3.00--2.43-----0.8314-0.83140.000.2960.00----0.00-413.86---620.46-------------2.470.00-------69.77------
Medical Marijuana Inc-100.00bn-100.00bn10.75m----0.1157----------0.019-----------22.66---23.11--70.58---145.521.79--0.0479--26.3039.07141.59---0.016--
Chromocell Therapeutics Corp0.00-7.38m10.76m4.00---------1.28-1.280.00-1.120.00----0.00-9,746.19-----------------13.23---------200.20------
Lotus Pharmaceuticals Inc70.79m1.72m10.81m233.000.07250.00112.800.15260.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Eterna Therapeutics Inc68.00k-21.68m10.93m8.00--4.90--160.73-4.08-4.080.01280.41280.0019--0.09888,500.00-60.69-169.05-75.78-223.00-173.53---31,864.71-682.61---33.190.7813-----68.8911.84---58.86--
ABVC Biopharma Inc152.43k-10.52m11.19m16.00--1.00--73.44-2.52-2.520.03521.060.0127--0.35149,526.88-90.65-103.38-171.60-231.54-98.1576.25-7,157.57-2,019.89---3.280.153---84.2885.3935.97------
Avalo Therapeutics Inc1.93m-31.54m11.22m19.00--1.19--5.83-381.36-381.366.949.110.0708128.501.87101,315.80-116.06-99.64-228.35-154.4233.2584.69-1,638.65-613.581.82-5.670.00---89.34-22.8324.28---22.48--
ELEVAI Labs Inc1.71m-4.30m11.26m18.00--2.94--6.58-0.2482-0.24820.09880.2208------95,143.89--------66.25---251.17--3.41-41.160.00--123.50---138.94------
Notable Labs Ltd310.00k-11.26m11.27m16.00--0.7459--36.36-3.08-3.080.09391.680.0126----19,375.00-45.79-52.02-56.70-62.0936.4560.19-3,633.55-3,636.93----0.0221---52.89-11.9365.13---50.69--
Monopar Therapeutics Inc0.00-7.61m11.73m10.00---------0.5289-0.52890.00--0.00----0.00-73.36-54.07-92.67-60.60------------0.00------20.10------
Chemomab Therapeutics Ltd - ADR0.00-24.22m11.93m20.00--0.0351-----42.37-42.370.0023.930.00----0.00-74.28---90.33--------------0.00------12.39------
Pioneer Green Farms Inc9.29k-403.37k11.94m6.00------1,285.15-0.0172-0.01720.0004-0.0260.01540.3035--1,548.33-66.94------41.44---4,341.98--0.0106-30.89--------35.41------
Data as of May 13 2024. Currency figures normalised to ELEVAI Labs Inc's reporting currency: US Dollar USD

Institutional shareholders

0.36%Per cent of shares held by top holders
HolderShares% Held
Diversify Advisory Services LLCas of 31 Mar 202452.50k0.30%
HRT Financial LLCas of 31 Dec 202310.24k0.06%
G1 Execution Services LLCas of 31 Mar 20240.000.00%
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.